Results 31 to 40 of about 19,748 (182)

Duodenal biopsy: an unexpected confirmatory test for a patient with al-amyloidosis

Sri Lanka Journal of Medicine, 2019
SSystemic AL- amyloidosis is a disorder of protein folding in which there is extra-cellular accumulation as β pleated fibrillar deposits of monoclonal immunoglobulin light chain fragments. AL- amyloidosis is a rare clinical entity.
S. Pirasath, T. Kumanan, G. Selvaratnam, V. Sujanitha, D. D. Dikowita   +4 more
doaj   +1 more source

Light‐chain amyloid myopathy isolated to skeletal muscles: A case report

Clinical Case Reports, 2020
Isolated amyloidosis, especially of amyloid light‐chain type, is an infrequent disease. Systemic chemotherapy for light‐chain amyloidosis isolated to skeletal muscles plays a key role to reduce clonal plasma cells producing aberrant immunoglobulin.
Toshihiro Matsukawa, Katsuki Eguchi, Ichizo Nishino, Kohei Okada, Kazuo Oshimi, Takuto Miyagishima   +5 more
doaj   +1 more source

Light chain amyloidosis: the heart of the problem

Haematologica, 2013
In this issue of Haematologica, Dinner et al. report the outcome of a pilot study of an oral regimen of lenalidomide in combination with dexamethasone and low-dose melphalan in 25 patients with light chain amyloidosis (AL), most of them with cardiac involvement.[1][1] The treatment proved to ...
MERLINI, GIAMPAOLO, PALLADINI, GIOVANNI
openaire   +4 more sources

Cutaneous light chain amyloidosis with multiple myeloma: A concise review

Hematology/Oncology and Stem Cell Therapy, 2019
Objective/Background: Cutaneous immunoglobulin (Ig) amyloid light-chain (AL) amyloidosis associated with overt multiple myeloma (MM) is rare and optimal treatment is not well defined.
Mirela Andrei, Jen Chin Wang
doaj   +1 more source

Syndrome in Question [PDF]

Anais Brasileiros de Dermatologia, 2015
Immunoglobulin light chain amyloidosis is the most common acquired systemic amyloidosis. Its presentation is often insidious and progressive, which may delay diagnosis.
Han MA, Meilan Chen, Juan Li, Ying Li, Shu Qiu   +4 more
doaj   +1 more source

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis

Hemato, 2021
Non-native immunoglobulin light chain conformations, including aggregates, appear to cause light chain amyloidosis pathology. Despite significant progress in pharmacological eradication of the neoplastic plasma cells that secrete these light chains, in ...
Gareth J. Morgan, Joel N. Buxbaum, Jeffery W. Kelly   +2 more
doaj   +1 more source

Cardiac amyloidosis in a kidney transplant recipient [PDF]

Journal of Nephropathology
Systemic amyloidosis is a collection of diseases caused by the deposition of protein fibrils in organ tissues, leading to significant morbidity. Cardiac amyloidosis, a rare and debilitating condition, can affect any organ in the body.
Bahareh Marghoob, Mohammad Hassan Fallahkohan   +1 more
doaj   +1 more source

Amyloidosis: a case series and review of the literature

Journal of Medical Case Reports, 2023
Background Systemic amyloidosis is group of disorders characterized by the accumulation of insoluble proteins in tissues. The most common form of systemic amyloidosis is light chain amyloidosis, which results from the accumulation of misfolded ...
Justin B. Senecal, Romel Abou-Akl, Pat Allevato, Ian Mazzetti, Caroline Hamm, Richa Parikh, Indryas Woldie   +6 more
doaj   +1 more source

QBP1 Peptide as a Potential Anti‐Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study

Advanced Science, EarlyView.
The anti‐amyloidogenic peptide QBP1 effectively halts human islet amyloid polypeptide (hIAPP) aggregation, preventing the formation of toxic β‐structured intermediates. Through a combination of biophysical assays, molecular dynamics, and cell‐based studies, QBP1 is shown to preserve β‐cell viability and metabolic homeostasis, positioning it as a ...
María M. Tejero‐Ojeda, Ada Bernaus Vives, Michał Wojciechowski, Dinh Quoc Huy Pham, Mateusz Chwastyk, Mario Vallejo, Anna Novials, Douglas V. Laurents, Mariano Carrión‐Vázquez   +8 more
wiley   +1 more source

Molecular Mobility of N‐Acetylgalactosamine‐Modified Cyclodextrins on a Polyrotaxane for Highly Efficient Liver Targeting of Antibody Chimeras and Genome‐Editing Ribonucleoproteins

Advanced Science, EarlyView.
Monovalent N‐acetylgalactosamine (GalNAc)‐modified polyrotaxane enables efficient liver targeting by utilizing ligand mobility. The sliding and rotating cyclic components i.e., cyclodextrin in the polyrotaxane dynamically cluster GalNAc moieties, thereby mimicking trivalent interactions with asialoglycoprotein receptors.
Toru Taharabaru, Keiichi Motoyama, Yuting Wen, Zhongxing Zhang, Xuehao Tian, Jun Li, Taishi Higashi   +6 more
wiley   +1 more source